RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
935. Fiorini F, Patrone E, Castelluccio A. Clinical investigation on
the hypolipidemic effect of simvastatin versus probucol in
hemodialysis patients. Clin Ther 145: 213-217, 1994
936. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I,
Maeda A, y cols. Effect of simvastatin on the lipid profile of
hemodialysis patients. Kidney Int 56(suppl 71): S219-S221,
1999
937. Nishizawa Y, Shoji T, Emoto M, y cols. Reduction of intermediate
density lipoprotein by pravastatin in hemo and peritoneal
dialysis patients. Clin Nephrol 43: 268-277, 1995.
938. Robson RA, Collins J, Johnson R, Kitching R, Searle M,
Walker R, y cols. Effects of simvastatin and enalapril on
serum lipoprotein concentrations and left ventricular mass in
patients on dialysis. The PERFECT Study Collaborative
Group. J Nephrol 10: 33-40, 1997
939. Saltissi D, Morgan C, Rigby R, Westhuyzen J. Safety and efficacy
of simvastatin in hypercholesterolemic patients undergoing
chronic renal dialysis. Am J Kidney Dis 39: 283-290,
2002
940. Matthys E, Schurgers M, Lamberigts G, Lameire N,
Vandecasteele N, Labeur C y cols. Effect of simvastatin on
the dyslipoproteinemia in CAPD patients. Atherosclerosis
86: 183-192, 1991
941. Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N,
Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic
patients on peritoneal dialysis. Nephrol Dial Transplant 15:
684-688, 2000
942. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ,
Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in
patients on hemodialysis: Effects on lipoproteins, C-reactive
protein and in vivo oxidized LDL. J Nephrol 16: 238-244,
2003
943. Seliger S, Stehman-Breen C. Are HMG-CoA reductase inhibitors
underutilized in dialysis patients? Semin Dialysis 16:
179-185, 2003
944. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE,
Crijns HJ y cols. Rationale, design, and baseline characteristics
of a trial of prevention of cardiovascular and renal disease
with fosinopril and pravastatin in nonhypertensive,
nonhypercholesterolemic subjects with microalbuminuria
(the Prevention of REnal and Vascular ENdstage Disease
Intervention Trial (PREVEND IT). Am J Cardiol 86: 635-638,
2000
945. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and
design of a trial improving outcome of type 2 diabetics on
hemodialysis. Die Deutsche Diabetes Dialyse Studie
Investigators. Kidney Int 71: S222-S226, 1999.
946. Baigent C, Wheeler DC. Should we reduce blood cholesterol
to prevent cardiovascular disease among patients with
chronic renal failure? Nephrol Dial Transplant 15: 1118-
1119, 2000.
947. Landray M, Baigent C Leaper C and the UK-HARP Steering
Committee. Biochemical safety and efficacy of co-administration
of ezetimibe and simvastatin among patients with
chronic kidney disease: the second UK-Heart and renal protection
(UK-HARP-II) study. Circulation 108 (17, suppl. IV):
736, 2003
948. Baigent C, Landry M. Study of Heart and Renal Protection
(SHARP). Kidney Int 63 (suppl 84): S207-S210, 2003.
949. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao
KV. Lovastatin treatment of hypercholesterolemia in renal
transplant recipients. Transplantation 49: 95-100, 1990.
950. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM,
Chia D, Ozawa M, y cols. The effect of pravastatin on acute
rejection after kidney transplantation. A pilot study.
Transplantation 61: 1469-1474, 1996
951. Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R,
Boddaert M, y cols. Comparison of pravastatin and lovastatin
in renal transplantation patients receiving cyclosporine.
Transplant Proc 1996; 28. 3126-3128, 1996
952. Arnadottir M, Eriksson LO, Germershausen JL, Thysell H.
Low dose simvastatin is a well tolerated and efficacius cholesterol
lowering agent in cyclosporine treated kidney transplant
recipients: Double blind, randomized, placebo controlled
study in 40 patients. Nephron 68: 57-62, 1994
953. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead
JF. Low dose simvastatin is safe in hyperlipidaemic renal
transplant patients. Nephrol Dial Transplant 8: 637-641,
1993
954. Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC,
Sarmento AM y cols. Therapy of post renal transplantation
hyperlipidaemia: comparative study with simvastatin and
fish oil. Nephrol Dial transplant 12: 2140-2143, 1997
955. Sahu K, Sharma R, Gupta A, Gulati S, Agarwal D, Kumar A y
cols. effect of lovastatin, an HMGCoA reductasa inhibitor,
on acute renal allograft rejection. Clin Transplant 15. 173-
175, 2001
956. Renders L, Mayer-Kadner I, Koch C, Scharffe S, Burkhardt K,
Veelken R, y cols. Efficacy and drugs interactions of the new
HMG-CoA reductase inhibitors cerivastatin and atorvastatin
in CsA trated renal transplant recipients. Nephrol Dial
Transplant 16: 141-146, 2001.
957. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B,
Germain MJ, Bastani B. The effects of lipid lowering agents
on acute renal allograft rejection. Transplantation 72: 223-
227, 2001.
958. Martinez-Castelao A, Grinyo JM, Gil-Vernet S, Seron D,
Castineiras MJ, Ramos R, y cols. Lipid lowering long term
effects of six different statins in hypercholesterolemic renal
transplant patients under cyclosporine immunosuppression.
Transplant Proc 34: 398-400, 2002.
959. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ,
Fellstrom B y cols. Effect of fluvastatin on acute renal allograft
rejection: a randomized multicenter trial. Kidney Int 60:
1990-1997, 2001
960. Igel M, Sudhop T, von Bergmann K. Metabolism and drug
interactions of 3-hydroxy-3 methylglutaryl cenzyme A
reductase inhibitors (statins). Eur J Clin Pharmacol 47: 357-
364, 2001
961. Stern R, Yang B, Horton M, Moore S, Abel RB, Olson SC.
Renal dysfunction does not alter the pharmacokinetics or
LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol
37: 816-819, 1997
962. Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of
fluvastatin in subjects with renal impairment and nephrotic
syndrome. J Clin Pharmacol 2002; 42: 312-318, 2002
963. Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford
NF. The pharmacokinetics of pravastatin in patients of chronic
hemodialysis. Eur J Clin Pharmacol 53: 117-121, 1997
964. Sica DA, Gehr TW. 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors and rhabdomyolysis: considerations in
the renal failure patient. Curr Opin Nephrol Hypertens 11:
123-133, 2002
216